Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

NCT04071223 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04071223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04071223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 29, 2020
Completion date
September 24, 2027
Enrollment
98 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, chromophobe renal cell carcinoma, clear cell renal cell carcinoma, collecting duct carcinoma, kidney medullary carcinoma, metastatic malignant neoplasm in the bone, papillary renal cell carcinoma, stage iv renal cell cancer ajcc v8, unclassified renal cell carcinoma